Loerop James 4/A

What Happened James Loerop, Chief Business Officer of Aclaris Therapeutics (ACRS), had restricted stock units (RSUs) vest and convert into common shares on February 1, 2026. A total of 33,500 RSUs settled into shares (11,250 + 7,500 + 14,750). To satisfy tax withholding obligations, 10,686 of those shares were withheld at $3.51 per share for a cash value of $37,508, leaving a net issuance to Loerop of 22,814 shares. The filings show the RSU conversions recorded as derivative exercises (code M) and the withholding as a tax payment (code F).

Key Details

• Transaction date: February 1, 2026 (reported in amended Form 4 filed Feb 5, 2026).
• Shares settled: 33,500 RSUs converted to common stock (11,250; 7,500; 14,750).
• Tax withholding: 10,686 shares withheld at $3.51/share = $37,508 (code F).
• Net shares delivered to insider: 22,814 (33,500 − 10,686).
• Post-transaction total shares owned: not specified in this filing.
• Footnotes: F1–F5 describe that these were restricted stock units (each RSU = one share) with multi-year vesting schedules (grants dated Feb 1 of 2022, 2023, and 2024) and F2 confirms shares were withheld to satisfy tax withholding.
• Amendment: This Form 4 amends the Feb 3, 2026 filing that incorrectly reported a Feb 1, 2025 transaction date — the amendment corrects that error.
• Transaction codes: M = exercise/conversion of derivative (RSU settlement); F = payment of tax liability via share withholding. No 10b5-1 plan or 10% owner status was reported.

Context This was a routine settlement of vested RSUs, not an open-market purchase or sale. The withholding of shares to cover taxes is a common, administrative step (similar to a cashless exercise) and does not by itself indicate buying or selling sentiment in the market.